Veronika Weyer-Elberich

Veronika Weyer-Elberich

Auto-generated profile, based on publicly available information

Veronika Weyer-Elberich

Institute of Biostatistics and Clinical Research, University of Münster, Münster, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2023 in Radiology
Verified
Journal Article
Closed access
SWStefanie Weigel
Stefanie Weigel
WHWalter Heindel
Walter Heindel
TDThomas Decker
Thomas Decker
VWVeronika Weyer-Elberich
Veronika Weyer-Elberich
LKLaura Kerschke
Laura Kerschke
FGfor the TOSYMA Screening Trial Study Group
for the TOSYMA Screening Trial Study Group
Background Breast cancer screening with digital breast tomosynthesis (DBT) plus synthesized mammography (SM) increases invasive tumor detection compared with digital mammography (DM). However, it is not known how the prognostic characteristics of the cancers detected with the two screening approaches differ. Purpose To compare invasive breast cancers detected with DBT plus SM (test arm) versus DM (control arm) screening with regard to tumor stage, histologic grade, patient age, and breast density. Materials and Methods This exploratory subanalysis of the Tomosynthesis plus Synthesized Mammography (TOSYMA) study, which is a multicenter randomized controlled trial embedded in the German mammography screening program, recruited women aged 50-70 years from July 2018 to December 2020. It compared invasive cancer detection rates (iCDRs), rate differences, and odds ratios (ORs) between the arms stratified by Union for International Cancer Control (UICC) stage (I vs II-IV), histologic grade (1 vs 2 or 3), age group (50-59 vs 60-70 years), and Breast Imaging Reporting and Data System categories of breast density (A or B vs C or D). Results In total, 49 462 (median age, 57 years [IQR, 53-62 years]) and 49 669 (median age, 57 years [IQR, 53-62 years]) participants were allocated to DBT plus SM and DM screening, respectively. The iCDR of stage I tumors with DBT plus SM was 51.6 per 10 000 women (255 of 49 462) and with DM it was 30.0 per 10 000 women (149 of 49 669). DBT plus SM depicted more stage I tumors with grade 2 or 3 (166 of 49 462, 33.7 per 10 000 women) than DM (106 of 49 669, 21.3 per 10 000 women; rate difference, +12.3 per 10 000 women [95% CI: 0.3, 24.9]; OR, 1.6 [95% CI: 0.9, 2.7]). DBT plus SM achieved the highest iCDR of stage I tumors with grade 2 or 3 among women aged 60-70 years with dense breasts (41 of 7364, 55.4 per 10 000 women; rate difference, +21.6 per 10 000 women [95% CI: -21.1, 64.3]; OR, 1.6 [95% CI: 0.6, 4.5]). Conclusion DBT plus SM screening appears to lead to higher detection of early-stage invasive breast cancers of grade 2 or 3 than DM screening, with the highest rate among women aged 60-70 years with dense breasts. Clinical trial registration no. NCT03377036 © RSNA, 2023 See also the editorial by Ha and Chang in this issue.

1 September 2025 in Radiology
Verified
Journal Article
Closed access
SWStefanie Weigel
Stefanie Weigel
HHHans-Werner Hense
Hans-Werner Hense
VWVeronika Weyer-Elberich
Veronika Weyer-Elberich
JGJoachim Gerß
Joachim Gerß
WHWalter Heindel
Walter Heindel
IWIngo Wendt
Ingo Wendt
A subanalysis of the TOmosynthesis plus SYnthesized MAmmography (TOSYMA) trial shows that digital breast tomosynthesis plus synthesized mammography screening had lower false-positive recall rates, especially in first-round participants, and higher false-positive biopsy rates than digital mammography, which were compensated by more detected breast cancers.